Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

Novo Nordisk also noted 44 documented adverse events associated with compounded liraglutide since 2017, including 38 serious cases and one death. Novo Nordisk warns that adding liraglutide to the ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts ... Novo’s older weight loss drug Saxenda and its insulin-degludec-based ...

Novo Nordisk cites 44 adverse events, including 38 serious cases and one death, linked to compounded liraglutide since 2017. Testing revealed impurities and fibril formation in unapproved ...

Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk®. Despite the launch of a genericized injected version of ...